Mazen Animal Health Receives Patent from the USPTO for its Oral Porcine Epidemic Diarrhea Virus (PEDV) Vaccine
- The USPTO issued the company a patent for its transformative technology to produce orally delivered animal vaccines by the number Patent US-11566255-B2, "Expression of PEDV Sequences in Plants and Plant Produced Vaccine for Same" on the 31st of Jan 2023
- The patent covers foundational technology for the company’s first vaccine product, the PEDV vaccine, which is expected to be launched in the year 2024
- Mazen's first product is expected to provide effective lactogenic immunity to piglets through oral PEDV antigens dosed to the sows during gestation
Ref: Natinal Hog Farmer | Image: Mazen Animal Health
Related News:- CardioRenal Systems’ RenalGuard Therapy Device Receives the US FDA’s Breakthrough Device Designation for Cardiac Surgery Associated AKI
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].